Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD7762 |
Synonyms | |
Therapy Description |
AZD7762 is an ATP-competitive CHK1/CHK2 inhibitor, which abrogates DNA damage-induced cell cycle checkpoints, and demonstrates antitumor activity when administered in combination with DNA-damaging agents (PMID: 18790776, PMID: 32335582, PMID: 31372095). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD7762 | AZD-7762 | CHK Inhibitor (Pan) 2 | AZD7762 is an ATP-competitive CHK1/CHK2 inhibitor, which abrogates DNA damage-induced cell cycle checkpoints, and demonstrates antitumor activity when administered in combination with DNA-damaging agents (PMID: 18790776, PMID: 32335582, PMID: 31372095). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 del | Advanced Solid Tumor | sensitive | AZD7762 | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line with knockout of FBXW7 demonstrated increased sensitivity to AZD7762 treatment compared to cells with wild-type FBXW7 in culture (PMID: 38032106). | 38032106 |
FBXW7 R465H | cervical cancer | sensitive | AZD7762 | Preclinical - Cell culture | Actionable | In a preclinical study, a cervical cancer cell line harboring FBXW7 R465H demonstrated increased sensitivity to AZD7762 treatment compared to a cell line with wild-type FBXW7 in culture (PMID: 38032106). | 38032106 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|